BLA 761080 · Hospira INC
Nivestym
Filgrastim-Aafi · Injection, Single-Dose · Leukocyte Growth Factor
Last checked: Nov 20, 2026Latest source record: Feb 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 20, 2018
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
1,650
302 Phase 3, 127 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Filgrastim" as an intervention, any sponsor and status, largest first.
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial InfarctionPivotal-lookingStatus unknown
Recardio, Inc.Industry
NCT05881382 · 4,100 participants (planned) · Start Sep 2023 · Primary completion Sep 2025
Drug: Dutogliptin + Filgrastim; Placebo · For: ST Elevation Myocardial Infarction
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)Pivotal-lookingCompleted
University Hospital MuensterAcademic, hospital or other
NCT00266136 · 3,500 participants · Start Jun 1999 · Primary completion Jan 2007
Drug: Cytarabine; Thioguanine and 3 more · For: Acute Myeloid Leukemia
Sites: Münster, Germany
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT00070564 · 3,294 participants · Start Nov 2003 · Primary completion Jan 2015
Drug: pegfilgrastim; AC regimen and 3 more · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 542 sites in all
- Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002611 · 3,031 participants · Start Jul 1995 · Primary completion Jun 2002
Drug: dactinomycin; filgrastim and 4 more · For: Kidney Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498716 · 2,199 participants · Start Aug 2, 2018 · Primary completion Aug 14, 2023
Drug: Atezolizumab; Paclitaxel and 2 more · For: Triple Negative Breast Cancer
Sites: Concord, California; Los Angeles, California; St. Helena, California · 364 sites in all
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00014222 · 2,104 participants · Start Dec 4, 2000 · Primary completion Feb 10, 2014
Drug: epoetin alfa; filgrastim and 5 more · For: Breast Cancer
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; La Jolla, California · 78 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nivestym* (Filgrastim-Aafi)
2024 spending
$15.4M
Beneficiaries
4,202
13,262 claims
Per beneficiary
$3,674
$315.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,466,154 |
| 2021 | $2,778,657 |
| 2022 | $7,646,197 |
| 2023 | $15,125,650 |
| 2024 | $15,436,839 |
Part B: Nivestym (Filgrastim-Aafi) · HCPCS Q5110
2024 spending
$5.3M
Beneficiaries
6,879
41,523 claims
Per beneficiary
$766
2024 ASP limit $0.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,560,249 |
| 2021 | $4,915,196 |
| 2022 | $4,194,131 |
| 2023 | $6,067,935 |
| 2024 | $5,271,910 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, et al. · J Clin Oncol 2015 · Practice Guideline, Research Support, Non-U.S. Gov't
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, et al. · J Clin Oncol 2003 · Clinical Trial, Multicenter Study
- Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB, West DC, Krailo MD, et al. · J Clin Oncol 2012 · Multicenter Study, Randomized Controlled Trial
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS, Bohlius J, Cameron DA, et al. · Eur J Cancer 2011 · Consensus Statement, Practice Guideline
- A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, et al. · Support Care Cancer 2018 · Meta-Analysis, Systematic Review
- Same-day pegfilgrastim and chemotherapy.
Lokich J · Cancer Invest 2005 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.